Stanley Laman Group Ltd. Sells 1,472 Shares of Bruker Co. (NASDAQ:BRKR)

Stanley Laman Group Ltd. reduced its position in Bruker Co. (NASDAQ:BRKR) by 1.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,736 shares of the medical research company’s stock after selling 1,472 shares during the quarter. Stanley Laman Group Ltd. owned approximately 0.06% of Bruker worth $3,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in BRKR. Fifth Third Bancorp increased its holdings in Bruker by 54.2% in the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company’s stock worth $46,000 after acquiring an additional 390 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Bruker by 15.4% during the first quarter. Handelsbanken Fonder AB now owns 32,300 shares of the medical research company’s stock worth $1,348,000 after purchasing an additional 4,300 shares during the period. Park Avenue Securities LLC increased its stake in shares of Bruker by 28.0% in the first quarter. Park Avenue Securities LLC now owns 9,469 shares of the medical research company’s stock worth $395,000 after purchasing an additional 2,074 shares in the last quarter. Washington Capital Management Inc. bought a new stake in shares of Bruker in the first quarter valued at approximately $908,000. Finally, UMB Bank n.a. raised its position in shares of Bruker by 45.8% in the first quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 416 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on BRKR shares. Barclays cut their price objective on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. UBS Group cut their price target on Bruker from $57.00 to $45.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Stifel Nicolaus reduced their price target on Bruker from $57.00 to $48.00 and set a “hold” rating for the company in a research report on Thursday, May 8th. Citigroup cut Bruker from a “strong-buy” rating to a “hold” rating and dropped their price objective for the stock from $50.00 to $40.00 in a report on Thursday, May 22nd. Finally, Wells Fargo & Company cut their target price on Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $56.22.

Bruker Stock Performance

NASDAQ:BRKR opened at $39.87 on Friday. The stock has a market cap of $6.04 billion, a P/E ratio of 52.46, a PEG ratio of 2.16 and a beta of 1.16. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The business’s 50-day moving average price is $38.27 and its two-hundred day moving average price is $48.06. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $72.94.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The company had revenue of $801.40 million for the quarter, compared to analysts’ expectations of $763.83 million. During the same period in the prior year, the business earned $0.53 earnings per share. Bruker’s revenue for the quarter was up 11.0% compared to the same quarter last year. As a group, equities analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Monday, June 16th will be given a $0.05 dividend. The ex-dividend date is Monday, June 16th. This represents a $0.20 annualized dividend and a yield of 0.50%. Bruker’s dividend payout ratio (DPR) is presently 38.46%.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien bought 2,608 shares of the business’s stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer now directly owns 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 27.30% of the stock is owned by insiders.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.